Novogen Inc. (NVGN)

Oncology Corporate Profile

Stock Performance

1.3357
0.0000

HQ Location

140 Wicks Road
NORTH RYDE NSW 2113, AUSTRALIA

Company Description

Novogen Limited and its subsidiaries engage in the research and development of pharmaceutical products, and marketing of consumer healthcare products. The company is developing various pharmaceutical products, including Phenoxodiol, a phase III investigational drug for late stage, chemoresistant ovarian cancer and prostate, and cervical cancers; Triphendiol, a phase I signal transduction inhibitor for the treatment of cholangiocarcinoma or bile duct cancer, and stage IIB through stage IV malignant melanoma; NV-128, a pre-clinical stage cancer compound to promote cancer cell death in multi-drug resistant ovarian cancer cells by targeting the AKT-mTOR pathway.

Website: http://www.novogen.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GDC-0084PI3K inhibitorGlioblastoma Multiforme (GBM)II
cantrixil / TRX-E-002-1superbenzopyran (SBP) therapyOvarian cancerI
anisina / ATM-3507anti-tropomyosin (ATM) therapyVarious cancer typesPreclinical
trilexium / TRX-E-002-1superbenzopyran (SBP) therapyVarious cancer typesPreclinical

View additional information on product candidates here »

Source


Souce: http://www.novogen.com

Recent News Headlines

Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma

10/31/2016 10:33 am

(MarketWatch) Oct 30, 2016 - Licensing of GDC-0084, a small molecule phosphoinositide-3-kinase (PI3K) inhibitor developed by Genentech, is ready to enter a phase II clinical trial in glioblastoma multiforme (GBM).

Government Agency Selects RCCA to Participate in Innovative "Oncology Care Model” Initiative

6/20/2016 12:02 pm

(New Jersey Online) June 20, 2016 - Regional Cancer Care Associates LLC, or RCCA, is one of a select group of oncology organizations nationwide invited by the Centers for Medicare and Medicaid Services (CMS) to participate in the agency's Oncology Care Model, or OCM.

Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer

12/20/2013 12:03 pm

(Yahoo! Finance) Dec 20, 2013 - Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University.

Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer

12/20/2013 12:00 pm

(Yahoo! Finance) Dec 20, 2013 - Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University.

Novogen, Yale Launch Venture to Develop Ovarian Cancer Drugs

11/6/2013 12:16 pm

(Genetic Engineering & Biotechnology News) Nov 6, 2013 - Novogen said today it is joining Yale University to launch a joint venture focused on fighting ovarian cancer by developing personalized approaches to chemotherapy.

Novogen, Yale Launch Venture to Develop Ovarian Cancer Drugs

11/6/2013 12:01 pm

(Genetic Engineering & Biotechnology News) Nov 6, 2013 - Novogen said today it is joining Yale University to launch a joint venture focused on fighting ovarian cancer by developing personalized approaches to chemotherapy.

Provectus Pharmaceuticals Presents Final Phase 2 Melanoma Data at ESMO 2012

10/2/2012 01:00 pm

(4-traders) Oct 2, 2012 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that final top-line data from its Phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the ESMO (European Society for Medical Oncology) 2012 Congress in Vienna, Austria on October 1, 2012.

Genomic Study of Rare Children's Cancer Yields Possible Prognostic Tool

8/9/2012 11:05 am

(Huntsman Cancer Institute) Aug 8, 2012 - A new study of the genetic makeup, or genome, of Ewing sarcoma, a rare cancer that strikes children, teenagers, and young adults, has produced multiple discoveries: a previously unknown sarcoma subtype, genetic factors related to long-term survival, and identification of a genetic change between the primary and metastatic stages of the disease that could lead to better, more targeted treatment.